Skip to content

Aerie initiated Buy at Guggenheim

September 8, 2020

Aerie Pharmaceuticals (AERI +2.9%) was initiated by Guggenheim analyst Dana Flanders with a Buy rating and price target of $20, indicating a upside of 67.8% from current levels.

Wall Street Analysts Rating is Bullish.

Aerie is expanding franchise in Japan, a $0.8B glaucoma market, market share 57 MM TRx, as Phase 3 trials expected to commence in Q4; currently exploring partnering opportunities.

Also expanding Aerie franchise in Europe, $1B glaucoma market, market share 105 MM units; Mercury 3 topline readout in Q3-results to inform commercialization strategy; Ireland plant approved for U.S. production.

Advancing Pipeline (Read More: Investor Presentation)

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: